Scientific research from the Lymphoma Clinic at Emory Winship Cancer Institute will be presented at three podium presentations and two poster sessions at the American Society of Hematology (ASH) 47th Annual Meeting and Exposition on December 10-13, 2005. The four-day event, which is being held at the Georgia World Congress Center in Atlanta, provides a forum for hematologists to discuss the latest, promising clinical and research discoveries. This year, nearly 20,000 attendees are expected.
"We're honored to have our scientific abstracts selected for podium and poster presentations at this year's American Society of Hematology meeting. It offers an opportunity to share our investigative findings and to participate in a dialogue on the most current critical issues in the field of hematology with our peers," says Christopher R. Flowers, MD, MIS, Assistant Professor of Hematology and Oncology and Clinical Director of the Center for Oncology Informatics at Winship.
Emory University's School of Medicine medical students Josiah Orina and Melody Smith, under the mentorship of Dr. Flowers, will be presenting scientific research at the "Promoting Minorities in Hematology" session, and the "Benefits and Risks of Hematologic Therapies" session. The following research projects from Dr. Flowers' laboratory will be presented at the 47th ASH Meeting.
 Determining the Benefits of Chemotherapy for Achieving Complete Response in Patients with Untreated Advanced Stage Follicular Lymphoma: A Systematic Review and Meta-Analysis. Although advanced stage follicular lymphoma (FL) is considered incurable with standard therapy, and early institution of therapy has not demonstrated benefits over watchful waiting, novel strategies such as lymphoma vaccines and maintenance rituximab provide opportunities for achieving prolonged disease-free intervals.
 Ex Vivo Fludarabine Selectively Depletes Human Naive T-Cell Subsets: A Step Toward Modifying Donor Lymphocyte Infusion. Ex vivo modification of donor lymphocytes with purine analogs (mDL) may help to minimize graft versus host disease (GvHD) while providing beneficial graft versus leukemia (GvL) effects. In a murine model system, we have shown that allogeneic donor splenocytes, treated with fludarabine ex vivo have significantly reduced GvHD activity when transferred to irradiated recipient mice, and retain anti-viral and GvL activities (Giver, 2003). This effect appears to be mediated by relative depletion of donor "naive" T-cells. As a first step toward developing mDL for use in patients, we sought to evaluate the effects of ex vivo fludarabine exposure on human T-cell subsets, and to determine the minimum dose of fludarabine required to achieve this effect.
 Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin's Lymphoma (NHL): A Phase 2 Study. Bortezomib (VELCADE) a novel, first-in-class proteasome inhibitor, is being investigated in the treatment of non-Hodgkin's lymphoma (NHL). Preclinical data with combined rituximab and Velcade suggest additive cytotoxic activity. This phase 2 study investigated the response rate to rituximab plus Velcade, weekly or twice-weekly, in patients with relapsed follicular lymphoma or marginal zone NHL.
 Systematic Review and Meta-Analysis of Radioimmunotherapy Regimens in Patients with Relapsed Follicular and Transformed non-Hodgkins Lymphomas. Numerous treatment options are available to patients with relapsed follicular lymphoma, ranging from watchful waiting to transplantation. At present, the optimal therapy for this patient population remains undefined.
For a complete schedule of programs and events at the 2005 Annual ASH Meeting and Exposition, visit www.hematology.org.